Regeneron Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors
I'm PortAI, I can summarize articles.
Regeneron Pharmaceuticals Inc. (REGN) shares fell 3.58% to $768.00 on Monday, marking the third consecutive day of losses. This decline occurred despite a positive trading session for the overall market, with the S&P 500 and Dow Jones rising. Regeneron's stock is now 6.47% below its 52-week high of $821.11. In comparison, competitors like Amgen and Moderna also saw declines, while Gilead Sciences experienced a rise of 1.24%. Trading volume for Regeneron was 1.3 million, surpassing its 50-day average of 991,766.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Dow Jones The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments